Last session

A

Agilent Technologies, Inc.

20

Dormant

Agilent pairs confident raised guidance with analyst buy consensus, yet our conviction model scores it dormant at 20, flagging a valuation narrative running ahead of macro momentum.

The thesis

Agilent sells analytical instrumentation to life sciences, diagnostics, and applied chemistry customers. Revenue grew 8.1 percent year over year, gross margin stands at 53.8 percent, and net margin is 19.5 percent. Management raised guidance and now expects 5.8 to 6 percent core growth with EPS of $6.12 to $6.15, roughly 10 percent earnings growth. Analysts consensus rates the stock a buy, but our conviction score of 20 says the macro tape is inactive, so the bull case rests entirely on execution while the stock trades at 34.2 times earnings.

Why now

Guidance was just raised on a confident tone, setting up a 10 percent earnings growth year against a 34.2 times multiple that leaves no room for slippage. The risk-off rotation that would normally reprice defensive healthcare names is inactive, so the tension between analyst enthusiasm and dormant macro signals is at its sharpest exactly now.

What to watch

Watch whether quarterly core growth lands inside the 5.8 to 6 percent band and EPS tracks the $6.12 to $6.15 range over the next two reports. Watch the risk-off rotation signal turning active and any drug pricing policy headline, as either resolves the gap between the buy consensus and the dormant conviction score.

Key risks

At 34.2 times earnings, any miss against the 5.8 to 6 percent core growth guide compresses the multiple twice. Drug pricing policy shocks and trial failures remain the recurring sector shocks that cut instrumentation demand. A risk-off rotation into or out of healthcare, currently inactive, could reprice the second-priciest stock market history warning directly into this valuation.

Theme exposure

Healthcare, Biotech & Devices

Direct

Agilent Technologies, Inc. operates in medical - diagnostics & research. That places it inside the Healthcare, Biotech & Devices story.

Upcoming catalysts

Nov 23, 2026: Earnings announcement

This brief is generated from our intelligence layers. Treat it as a starting point, not a final word.

A media publication. Not investment advice. Not a recommendation.

Decifer Markets is a media publication. Nothing here is investment advice, a recommendation, or an offer to buy or sell any security.

DisclaimerTermsPrivacyAbout